Richard D. Carvajal
机构: Northwell Health Cancer Institute
每年引用次数
引用次数
引用: 38,912
H-指数: 73
I10-指数 : 226
出版物: 450
Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan.
Jasmine H. Francis , Christopher A. Barker , Vivian T. Yin , Richard D. Carvajal
Ocular Oncology and Pathology 5 ( 3) 186 -189
1
2019
Pediatric sunscreen coverage by medicaid as a primary prevention strategy to reduce melanoma burden: a cost-effectiveness analysis
Dawn Queen , Christine Lauren , RD Carjaval , Megan H Trager
J Clin Pathw 6 66 -66
1
2021
Ddx43 as a biomarker of resistance to mek1/2 inhibitors
Grazia Ambrosini , Raya KHANIN , Richard CARVAJAL , Gary K SCHWARTAZ
2015
Abstract IA14: Immunosensitivity and resistance in advanced uveal melanoma
Richard D. Carvajal
Cancer Research 80
2020
Cellular therapy for the treatment of solid tumors.
Richard D. Carvajal , Joseph M. Grimes , Pawel Muranski
Transfusion and Apheresis Science 60 ( 1) 103056
2021
Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Mark D. Pegram , Daniel Catenacci , Marcin Kowanetz , Shirish M. Gadgeel
Cancer Research 81
2021
OncoTree: A Cancer Classification System for Precision Oncology.
Ghassan K. Abou-Alfa , Lynette Sholl , Lynette Sholl , Hikmat A. Al-Ahmadie
JCO clinical cancer informatics 5 ( 5) 221 -230
2021
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal , Sophie Piperno-Neumann , Ellen Kapiteijn , Paul B. Chapman
Journal of Clinical Oncology 36 ( 12) 1232 -1239
94
2018
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
Todd Michael Bauer , Mrinal M. Gounder , Amy M. Weise , Gary K. Schwartz
Journal of Clinical Oncology 36 11514 -11514
12
2018
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).
Funda Meric-Bernstam , Nizar M. Tannir , James Walter Mier , Angela DeMichele
Journal of Clinical Oncology 34 4568 -4568
17
2016
A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.
Alexander Noor Shoushtari , Ragini Reiney Kudchadkar , Katherine Panageas , Rashmi Krishna Murthy
Journal of Clinical Oncology 34 ( 15_suppl) 9511 -9511
21
2016
Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.
Kimberly Mayumi Komatsubara , Alexander Noor Shoushtari , Sapna Pradyuman Patel , Parisa Momtaz
Journal of Clinical Oncology 35
1
2017
Outcomes of melanoma brain metastases treated with stereotactic radiosurgery with and without concurrent immune checkpoint therapy.
Jessica Yang , Laurent Dercle , Andrew M. Yaeh , Randy Yeh
Journal of Clinical Oncology 35
1
2017
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Sophie Piperno-Neumann , James Larkin , Richard D. Carvajal , Jason J. Luke
Molecular Cancer Therapeutics 19 ( 4) 1031 -1039
6
2020
Melanoma mutagenesis and aberrant cell signaling.
Danielle M. Bello , Charlotte E. Ariyan , Richard D. Carvajal
Cancer Control 20 ( 4) 261 -281
26
2013
Use of antibody arrays to probe exosome and extracellular vesicle mediated functional changes in cells.
Grazia Ambrosini , Blake Ebert , Richard D. Carvajal , Gary K. Schwartz
Methods in Enzymology 645 43 -53
2020
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial
Richard D. Carvajal , Jeffrey A. Sosman , Jorge Fernando Quevedo , Mohammed M. Milhem
JAMA 311 ( 23) 2397 -2405
250
2014
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Alain P. Algazi , Katy K. Tsai , Alexander N. Shoushtari , Rodrigo R. Munhoz
Cancer 122 ( 21) 3344 -3353
167
2016
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Jason J. Luke , Margaret K. Callahan , Michael A. Postow , Emanuela Romano
Cancer 119 ( 20) 3687 -3695
141
2013
Clinico‐morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients
Viswanath Reddy Belum , Alyx C. Rosen , Natalia Jaimes , George Dranitsaris
Cancer 121 ( 1) 60 -68
17
2015